Table 1.
Baseline characteristics
| Characteristic | All | Elderly (≥75 yr) | Nonelderly (18–74 yr) | P Value |
|---|---|---|---|---|
| N (%) | 464 | 90 (19) | 374 (81) | |
| Age (yr), mean (SD) | 59.9 (15.7) | 81.3 (4.9) | 54.8 (12.3) | |
| Men, n (%) | 237 (51.0) | 44 (48.8) | 193 (51.6) | 0.64 |
| Ancestry, n (%) | ||||
| European American | 230 (49.6) | 66 (73.3) | 164 (43.8) | <0.001 |
| African American | 218 (47.0) | 24 (26.7) | 194 (51.9) | |
| Hispanic | 16 (3.4) | 0 | 16 (4.3) | |
| HD vintage (d) | ||||
| Mean (SD) | 629 (1180) | 547 (1063) | 649 (1207) | 0.47 |
| Median (25th, 75th percentiles) | 21 (21, 777) | 21 (21, 812) | 21 (21, 774) | |
| Cause of end stage kidney disease, n (%) | ||||
| Diabetes | 167 (36.0) | 32 (35.6) | 135 (36.1) | 0.92 |
| GN | 65 (14.0) | 4 (4.4) | 61 (16.3) | 0.004 |
| Hypertension-attributed | 70 (15.1) | 15 (16.7) | 55 (14.7) | 0.64 |
| AKI | 30 (6.5) | 9 (10) | 21 (5.6) | 0.13 |
| Autosomal dominant polycystic kidney disease | 8 (1.7) | 0 | 8 (2.1) | 0.16 |
| Paraproteinemia | 13 (2.8) | 1 (1.1) | 12 (3.2) | 0.28 |
| Comorbidities, n (%) | ||||
| Coronary artery disease | 147 (31.7) | 46 (51.1) | 101 (27.0) | <0.001 |
| Diabetes mellitus | 260 (56.0) | 52 (57.8) | 208 (55.6) | 0.71 |
| Congestive heart failure | 143 (30.8) | 44 (48.9) | 99 (26.5) | <0.001 |
| Hypertension | 434 (93.5) | 85 (94.4) | 349 (93.3) | 0.69 |
| Peripheral vascular disease | 73 (15.7) | 18 (20.0) | 55 (14.7) | 0.22 |
| Medications, n (%) | ||||
| Immunosuppressant | 26 (5.6) | 1 (1.1) | 25 (6.6) | 0.05 |
Age is expressed in years at study entry. Immunosuppressant medications included prednisone, cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, azathioprine, methotrexate, or chemotherapy.